Home Newsfeeds JP Morgan Upgrades Vroom to Neutral

JP Morgan Upgrades Vroom to Neutral

JP Morgan analyst Rajat Gupta upgrades Vroom (NASDAQ:VRM) from Underweight to Neutral.

byBenzinga Newsdesk

November 17, 2022

1 minute read

JP Morgan analyst Rajat Gupta upgrades Vroom (NASDAQ:VRM) from Underweight to Neutral.

NeuroMetrix Q2 EPS $(0.17) Down From $(0.13) YoY, Sales $2.10M Down From $2.21M YoY

By Benzinga Newsdesk

July 21, 7:10 AM

NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(0.17) per share. This is a 30.77 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $2.10 million in sales

NURO

SuRo Capital Corp. Will Commence A Modified Dutch Auction Tender Offer To Repurchase Up To 2M Shares Of Its Common Stock At A Price Per Share Not Less Than $4.00 And Not Greater Than $5.00 In $0.10 Increments, Using Available Cash.

By Happy Mohamed

February 14, 5:31 PM

SuRo Capital Corp. ("SuRo Capital", the "Company", "we", "us", and "our") (Nasdaq:

SSSS

Novocure Has Enrolled The Final Patient In The Pivotal METIS Study Evaluating The Efficacy Of Tumor Treating Fields (TT Fields) Therapy Following Stereotactic Radiosurgery For Brain Metastases Resulting From Non-small Cell Lung Cancer

By Benzinga Newsdesk

March 1, 8:09 AM

Following the completion of enrollment, patients will be followed for a minimum of 12 months.

NVCR

Regeneron Builds On Together For CHANGE Initiative With 5-Year, $5M Commitment To Fuel The STEM Talent Pipeline In Nashville, TN

By Benzinga Newsdesk

October 18, 9:32 AM

Commitment builds on Regeneron's longstanding efforts to develop the STEM talent pipeline as lead sponsor of the premier high school competitions, the Regeneron Science Talent Search (STS) and Regeneron International

REGN

JP Morgan Upgrades Vroom to Neutral

Related Posts

NeuroMetrix Q2 EPS $(0.17) Down From $(0.13) YoY, Sales $2.10M Down From $2.21M YoY

SuRo Capital Corp. Will Commence A Modified Dutch Auction Tender Offer To Repurchase Up To 2M Shares Of Its Common Stock At A Price Per Share Not Less Than $4.00 And Not Greater Than $5.00 In $0.10 Increments, Using Available Cash.

Novocure Has Enrolled The Final Patient In The Pivotal METIS Study Evaluating The Efficacy Of Tumor Treating Fields (TT Fields) Therapy Following Stereotactic Radiosurgery For Brain Metastases Resulting From Non-small Cell Lung Cancer

Regeneron Builds On Together For CHANGE Initiative With 5-Year, $5M Commitment To Fuel The STEM Talent Pipeline In Nashville, TN